Y'S THERAPEUTICS

Y's Therapeutics

#People #More

Y'S THERAPEUTICS

Status:
Active


Current Employees Featured

not_available_image

Shinro Kato
Shinro Kato President & CEO @ Y's Therapeutics
President & CEO

More informations about "Y's Therapeutics"

Y's Therapeutics: Drug pipelines, Patents, Clinical trials - Synapse

Aug 7, 2023 Explore Y's Therapeutics with its drug pipeline, therapeutic area, technology platform, 1 news. Data. Feature. Plans. Sign Up for Free. Request Demo. Sign Up for Free. …See details»

Y-mAbs Therapeutics, Inc. | Home

Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.See details»

Y's Therapeutics - Crunchbase Company Profile & Funding

View contacts for Y's Therapeutics to access new leads and connect with decision-makers.See details»

Ystop - Drug Targets, Indications, Patents - Synapse - Patsnap

Ystop, Initially developed by Y's Therapeutics, Inc., Now, its global highest R&D status is Discontinued, Therapeutic Areas: Neoplasms. ... Originator Organization. Y's Therapeutics, …See details»

Y's Therapeutics - Products, Competitors, Financials, Employees ...

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and …See details»

Y's Therapeutics, Inc. - VentureRadar

Anthos Therapeutics USA n/a Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients. …See details»

Y's Therapeutics - LinkedIn

Y's Therapeutics Biotechnology Research Follow Report this company About us Industry Biotechnology Research Company size 11-50 employees ...See details»

Y's Therapeutics: Contact Details and Business Profile

Y's Therapeutics is a Biotechnology Research company based at 230 Park Ave Ste 3350, New York City, New York 10169, US founded in Jan. 1, 2014, midnight. View Top Employees from …See details»

Y's Therapeutics Co. Ltd: Contact Details and Business Profile

Y's Therapeutics is a privately held biopharmaceutical company engaged in the R&D of novel therapeutics for the treatment of inflammation-mediated diseases, cancer and other unmet …See details»

Y's Therapeutics - Tech Stack, Apps, Patents & Trademarks

Edit IT Spend by Aberdeen Section. This year, Y's Therapeutics is projected to spend $407.7K Y's Therapeutics is projected to spend $407.7KSee details»

Y's Therapeutics Co. Ltd. - BioCentury Company Profiles - BCIQ

Jun 25, 2009 Y's Therapeutics Co. Ltd. - BioCentury Company Profiles for the biopharma industrySee details»

Y's Therapeutics Co., Ltd. Initiates Phase II Clinical ... - BioSpace

TOKYO, Nov. 29 /PRNewswire/ -- Y’s Therapeutics Co., Ltd., a privately held biopharmaceutical company, announced the initiation of a Phase II clinical program of YSPSL for prevention of …See details»

Y's Therapeutics - Contacts, Employees, Board Members

Organization. Y's Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Highlights. Employee Profiles 1. Contacts 1. ... Y's Therapeutics has 1 current …See details»

Y's Therapeutics, Inc. Clinical-Stage Compound YSPSL Granted

BURLINGAME, Calif., July 20 /PRNewswire/ -- Y's Therapeutics, Inc. said today that the U.S. Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) …See details»

Y's Therapeutics and Abmaxis Announce Antibody Collaboration

MOUNTAIN VIEW, Calif. and TOKYO. Y's Therapeutics Co., Ltd. and Abmaxis, Inc., both privately held biopharmaceutical companies, have entered into an agreement to collaborate on …See details»

YS-IL6 - Drug Targets, Indications, Patents - Synapse

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.See details»

Kissei Licenses Monoclonal Antibody from Y's Therapeutics

Y's Therapeutics (www.ysthera.com) and Kissei Pharmaceutical announced on September 10 that they have concluded a license agreement that gives Kissei the exclusive rights to develop …See details»

Research programme: interleukin-6 inhibitors - Y's Therapeutics

Nov 4, 2017 Y's Therapeutics is conducting a research programme known as YSIL6, to investigate small molecule, oral inhibitors of IL-6 (interleukin-6) for the treatment of ... If your …See details»

YSTH2 - Drug Targets, Indications, Patents - Synapse

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»